Procarbazine genotoxicity in the Muta(TM)Mouse; strong clastogenicity and organ-specific induction of lacZ mutations

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 444, Issue 2, 1999, Pages 269-281

  Suzuki, Takayoshi ^a   Uno, Yoshifumi ^b   Idehara, Kenji ^c   Baba, Tsuneo ^c   Maniwa, Jiro ^d   Ohkouchi, Akiko ^b   Wang, Xue ^a   Hayashi, Makoto ^a   Sofuni, Toshio ^a   Tsuruoka, Masaki ^e   Miyajima, Hirofumi ^e   Kondo, Koji ^e  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

^c DAICEL CORPORATION   (Japan)

^d Zeneca KK Pharmaceuticals   (Japan)

^e SHIONOGI AND CO LTD   (Japan)

Author keywords

lacZ; Muta(TM)Mouse; Procarbazine; Tissue specific mutagenesis; Transgenic mouse

Indexed keywords

ANTINEOPLASTIC AGENT; ENVIRONMENTAL MUTAGEN; PROCARBAZINE; CARCINOGEN; MUTAGENIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENOTOXICITY; HEMATOPOIETIC CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MICRONUCLEUS TEST; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; TARGET ORGAN; TISSUE SPECIFICITY; TRANSGENIC MOUSE; ANIMAL; ANTIBODY SPECIFICITY; LACTOSE OPERON; MALE; TIME;

ANIMALS; CARCINOGENS; LAC OPERON; MALE; MICE; MICE, TRANSGENIC; MICRONUCLEUS TESTS; MUTAGENS; MUTATION; ORGAN SPECIFICITY; PROCARBAZINE; TIME FACTORS;

EID: 0032882462     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(99)00060-1     Document Type: Article

References (38)

1. Andrieu J.M., Ifrah N., Payen C., Fermanian J., Coscas Y., Flandrin G. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J. Clin. Oncol. 8:1990;1148-1154.
2. Kaldor J.M., Day N.E., Hemminki K. Quantifying the carcinogenicity of antineoplastic drugs. Eur. J. Cancer Clin. Oncol. 24:1988;703-711.
3. International Agency for Research on Cancer Procarbazine hydrochloride. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 26:1981;311-339.
4. R.A. Prough, D.J. Tweedie, Procarbazine, in: G. Powis, R.A. Prough (Eds.), Metabolism and Action of Anti-Cancer Drugs, Taylor and Francis, London, pp. 29-47.
5. 6-methylguanine in humans and rodents treated with procarbazine. Carcinogenesis. 15:1994;1675-1680.
6. Suter W. Mutagenicity of procarbazine for V79 Chinese hamster fibroblasts in the presence of various metabolic activation systems. Mutagenesis. 2:1987;27-32.
7. Waters M.D., Stack H.F. The short-term test activity profile for procarbazine hydrochloride. Mutagenesis. 3:1988;89-94.
8. Romagna F., Matsumura H., Watanabe M., Kato T., Shirasu Y., Ohmori K., Yamada H., Sasaki Y.F. Micronucleus evaluation in peripheral blood reticulocytes of mice treated with procarbazine hydrochloride or mitomycin C. Mutat. Res. 278:1992;197-204.
9. Vian L., Bichet N., Gouy D. The in vitro micronucleus test on isolated human lymphocytes. Mutat. Res. 291:1993;93-102.
10. Myhr B.C. Validation studies with Muta Mouse: a transgenic mouse model for detecting mutations in vivo. Environ. Mol. Mutagen. 18:1991;308-315.
11. Ashby J., Gorelick N.J., Shelby M.D. Mutation assays in male germ cells from transgenic mice: overview of study and conclusions. Mutat. Res. 388:1997;111-122.
12. Goldstein L.S. Dominant lethal mutations induced in mouse spermatogonia by antineoplastic drugs. Mutat. Res. 140:1984;193-197.
13. Kratochvilova J., Favor J., Neuhauser-Klaus A. Dominant cataract and recessive specific-locus mutations detected in offspring of procarbazine-treated male mice. Mutat. Res. 198:1988;295-301.
14. Suzuki T., Hayashi M., Sofuni T., Myhr B.C. The concomitant detection of gene mutation and micronuclei induction by mitomycin C in vivo using lacZ transgenic mice. Mutat. Res. 285:1993;219-224.
15. Hayashi M., Morita T., Kodama Y., Sofuni T., Ishidate M. Jr. The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange-coated slides. Mutat. Res. 245:1990;245-249.
16. Piegorsch W.W., Lockhart A.C., Carr G.J., Margolin B.H., Brooks T., Douglas G.R., Liegibel U.M., Suzuki T., Thybaud V., van Delft J.H., Gorelick N.J. Sources of variability in data from a positive selection lacZ transgenic mouse mutation assay: an interlaboratory study. Mutat. Res. 388:1997;249-289.
17. Suzuki T., Hayashi M., Sofuni T. Initial experiences and future directions for transgenic mouse mutation assays. Mutat. Res. 307:1994;489-494.
18. Suzuki T., Itoh S., Nakajima M., Hachiya N., Hara T. Target organ and time-course in the mutagenicity of five carcinogens in Muta™Mouse; a summary report of the second collaborative study on the transgenic mutation assay by JEMS/MMS. Mutat. Res. (this issue). 444:1999;259-268.
19. Morita T., Asano N., Awogi T., Sasaki Y.F., Sato S., Shimada H., Sutou S., Suzuki T., Wakata A., Sofuni T., Hayashi M. Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B) the summary report of the 6th collaborative study by CSGMT/JEMS·MMS. Mutat. Res. 389:1997;3-122.
20. Nowell P.C. Genetic alterations in leukemias and lymphomas: impressive progress and continuing complexity. Cancer Genet. Cytogenet. 94:1997;13-19.
21. CSGTM (The collaborative study group for the transgenic mouse mutation assay), Organ variation in the mutagenicity of ethylnitrosourea in Muta Mouse: results of the collaborative study on the transgenic mutation assay by JEMS/MMS, The Collaborative Study Group for the Transgenic Mouse Mutation Assay Mammalian Mutagenesis Study Group of the Environmental Mutagen Society of Japan, Environ. Mol. Mutagen. 28 (1996) 363-375.
22. 6-methylguanine. Carcinogenesis. 18:1997;2191-2196.
23. Mirsalis J.C, Provost G.S., Matthews C.D., Hamner R.T., Schindler J.E., O'Loughlin K.G., MacGregor J.T., Short J.M. Induction of hepatic mutations in lacI transgenic mice. Mutagenesis. 8:1993;265-271.
24. Andrew S.E., McKinnon M., Cheng B.S., Francis A., Penney J., Reitmair A.H., Mak T.W., Jirik F.R. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proc. Natl. Acad. Sci. U.S.A. 95:1998;1126-1130.
25. Hayward J.J., Shane B.S., Tindall K.R., Cunningham M.L. Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene. Carcinogenesis. 16:1995;2429-2433.
26. Shephard S.E., Sengstag C., Lutz W.K., Schlatter C. Mutations in liver DNA of lacI transgenic mice (Big Blue) following subchronic exposure to 2-acetylaminofluorene. Mutat. Res. 302:1993;91-96.
27. Suzuki T., Itoh T., Hayashi M., Nishikawa A., Ikezaki S., Furukawa F., Takahashi M., Sofuni T. Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue® mice. Environ. Mol. Mutagen. 28:1996;348-353.
28. Itoh T., Suzuki T., Wang X., Hayashi M., Nishikawa A., Ikezaki S., Furukawa F., Takahashi M., Sofuni T. In vivo mutagenicity of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in lacI transgenic mice. Mutat. Res. 379:1997;S147.
29. Ashby J., Tinwell H. Dosing regimens for transgenic mouse mutation assays: the dangers of facing in two directions at the same time. Environ. Mol. Mutagen. 25:1995;266-268.
30. Mirsalis J. Dosing regimens for transgenic animal mutagenesis assays. Environ. Mol. Mutagen. 21:1993;118-121.
31. Gorelick N.J. Overview of mutation assays in transgenic mice for routine testing. Environ. Mol. Mutagen. 25:1995;218-230.
32. Heddle J.A., Shaver-Walker P., Tao K.S., Zhang X.B. Treatment protocols for transgenic mutation assays in vivo. Mutagenesis. 10:1995;467-470.
33. Sofuni T., Suzuki T., Hayashi M. Initial consideration for use of transgenic mutation assays in a regulatory submission. Environ. Mol. Mutagen. 28:1996;443-446.
34. Douglas G.R., Gingerich J.D., Soper L.M., Jiao J.M. Toward an understanding of the use of transgenic mice for the detection of gene mutations in germ cells. Mutat. Res. 388:1997;197-212.
35. Inouye T., Imanishi H., Watanabe M., Sasaki Y.F., Shirasu Y., Ando N., Ishii S. Micronucleus test with procarbazine hydrochloride administered by intraperitoneal injection and oral gavage. Mutat. Res. 223:1989;411-414.
36. +/-) locus of mouse lymphoma assay. Mutagenesis. 3:1988;83-87.
37. Hakura A., Tsutsui Y., Sonoda J., Kai J., Imade T., Shimada M., Sugihara Y., Mikami T. Comparison between in vivo mutagenicity and carcinogenicity in multiple organs by benzo[a]pyrene in the lacZ transgenic mouse (Muta Mouse). Mutat. Res. 398:1998;123-130.
38. Nagao M., Fujita H., Ochiai M., Wakabayashi K., Sofuni T., Matsushima T., Sugimura T., Ushijima T. No direct correlation between mutant frequencies and cancer incidence induced by MeIQ in various organs of Big Blue mice. Mutat. Res. 400:1998;251-257.